James Foster Sells 75,000 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $230.59 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $236.62. The firm has a market cap of $11.11 billion, a PE ratio of -61.33, a P/E/G ratio of 2.62 and a beta of 1.39. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The business has a 50-day moving average price of $180.60 and a 200 day moving average price of $184.34.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently bought and sold shares of the company. National Bank of Canada FI raised its holdings in shares of Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the last quarter. Gotham Asset Management LLC grew its holdings in Charles River Laboratories International by 17.3% in the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock valued at $49,403,000 after purchasing an additional 46,594 shares during the period. Contravisory Investment Management Inc. purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth $1,223,000. Nordea Investment Management AB raised its holdings in shares of Charles River Laboratories International by 43.6% in the 4th quarter. Nordea Investment Management AB now owns 54,694 shares of the medical research company’s stock worth $10,985,000 after purchasing an additional 16,616 shares during the period. Finally, Confluence Investment Management LLC lifted its position in Charles River Laboratories International by 10.1% during the fourth quarter. Confluence Investment Management LLC now owns 105,626 shares of the medical research company’s stock valued at $21,070,000 after buying an additional 9,663 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CRL has been the subject of a number of recent analyst reports. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday. Barclays raised their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.